Data as of Apr 17
| +0.04 / +2.37%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 5.00 and a low estimate of 3.50. The median estimate represents a +131.21% increase from the last price of 1.73.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.